Effect of age and gender on the pharmacokinetics of eprosartan

British Journal of Clinical Pharmacology

Volumn 46, Issue 3, 1998, Pages 267-270

  Tenero, David M ^a,d   Martin, David E ^b   Miller, Ann K ^a   Ilson, Bernard ^b   Boike, Steven C ^b   Zariffa, Névine ^c   Jorkasky, Diane K ^b  

^a SmithKline Becchani Pliannacenticals ^*

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c SmithKline Beccham Phannacenticals   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Age; Angiotensin II receptor antagonist; Eprosartan; Gender; Pharmacokinetics

Indexed keywords

EPROSARTAN;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FEMALE; GENDER; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

ACRYLATES; ADULT; AGED; AGING; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; FEMALE; HALF-LIFE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PREMENOPAUSE; PROTEIN BINDING; SEX FACTORS; THIOPHENES;

EID: 0031668830     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00778.x     Document Type: Article

References (10)

1. Jackson EK, Garrison JC. Renin and angiotensin. In Tlie Pliarinacological Basis of Tlicrapeiitics, Ninth edn, eds Gilman AG, Hardman JG, Limbird LE, New York: McGraw-Hill 1996; 733-758.
2. Edwards RM, Aiyar N, Ohlstein EH, et al Pharmacological characterization of the non-peptide angiotensin II receptor antagonist, SK&F 108566. J Phannacol Exp Tlier 1992; 260: 175-181.
3. Lundberg DE, Person CR, Knox S, Cyronak M. Determination of SK&F. 108566 in human plasma by solidphase extraction cleanup and reversed-phased highperformance liquid chromatography. J Chromatogr B 1998; 707: 328-333.
4. Cox P, Bush B, Gorycki P, et al. The metabolic fate of eprosartan in healthy volunteers. Exp Tax Patliol 1996; 48(Suppl: II): 75-82.
5. Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. EurJ Drug Metab Pliarmacokinct 1996; 21: 123-128.
6. Tenero D, Martin D, Ilson B, et al. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biophannaceiitia & Drug Dispos (in press). 7 Holt PR. Intestinal absorption and malabsorption. In Tlie aging gut: patliopliysiology, diagnosis, and management, 1st edn, eds Tester EC, New York, Masson Publishing 1983; 33-56.
7. Data on File, SmithKline Beecham Pharmaceuticals. King of Prussia, PA.
8. Vachharajani N, Shyu WC, Smith R, Chang SY, Greene D, Barbhaiya R. The effects of age and gender on the pharmacokinetics of irbesartan. Phann Res 1995; 12: S388.
9. Vachharajani N, Shyu WC, Greene D, Barbhaiya R. The effect of age on the pharmacokinetics of irbesartan. J Clin Phannacol 1997; 37: 872.
10. Battle M, Klamerus K, Neefe D, Jusko W, Burghart P, Mayer P. The effects of age and gender on the pharmacokinetics and pharmacodynamics of tasosartan in patients with stage 1-2 essential hypertension. Pliannacotherapy 1997; 17: 1114.